Resources
Advanced Search
Start Free Trial
Talk With Sales
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
ATXCo
CB Rank
2387853
Heat Score
25
Save
Actions
ATXCo core asset is PAT-409, a Phase I ready autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF).
Acquired by
Blade Therapeutics
Private
Therapeutics
ATXCo
Section: Overview
Actions